Literature DB >> 1920306

Auranofin treatment in early rheumatoid arthritis may postpone early retirement. Results from a 2-year double blind trial.

G Borg1, E Allander, E Berg, U Brodin, A From, L Trang.   

Abstract

The effect of early vs delayed initiation of slow acting antirheumatic drug (SAARD) therapy on the ability to maintain regular work, was evaluated in 83 patients with early rheumatoid arthritis (RA) in a placebo controlled, double blind 24-month study. The estimated probability to maintain working ability was higher in the early treatment group, especially during the second study year. Predicting factors were age, type of work, degree of disability and number of swollen joints. Despite the difficulties in interpreting the results due to the complexity of the underlying socioeconomical and labor market situation, the study supports early treatment in RA with regard to the maintenance of normal life.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1920306

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

Review 1.  Predictive factors of work disability in rheumatoid arthritis: a systematic literature review.

Authors:  E M de Croon; J K Sluiter; T F Nijssen; B A C Dijkmans; G J Lankhorst; M H W Frings-Dresen
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 2.  The costs of rheumatoid arthritis.

Authors:  S H Allaire; M J Prashker; R F Meenan
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

3.  Work disability is related to the presence of arthritis and not to a specific diagnosis. Results from a large early arthritis cohort in Argentina.

Authors:  Gustavo Citera; Hernan Maldonado Ficco; Rodolfo S Pérez Alamino; Fernando Dal Pra; Veronica Lencina; Luciana Casalla; Mariana Benegas; Oscar Rillo; Alberto Berman; Ana Lucia Barbaglia; Veronica Bellomío; Maria Haye Salinas; Ana C Alvarez; Francisco Caeiro; Josefina Marcos; Adrian Salas; Antonio Catalán Pellet; Lorena Techera; Anastasia Secco; Sergio Paira; Federico Ceccato; Zaida Bedrán; Enrique R Soriano; Josefina Marin; Gabriela Salvatierra; Maria Elena Crespo
Journal:  Clin Rheumatol       Date:  2014-11-27       Impact factor: 2.980

4.  Sick leave as a predictor of job loss in patients with chronic arthritis.

Authors:  Petronella D M de Buck; Geertruida H de Bock; Frank van Dijk; Wilbert B van den Hout; Jan P Vandenbroucke; Theodora P M Vliet Vlieland
Journal:  Int Arch Occup Environ Health       Date:  2006-05-20       Impact factor: 3.015

5.  Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS).

Authors:  A Young; J Dixey; E Kulinskaya; N Cox; P Davies; J Devlin; P Emery; A Gough; D James; P Prouse; P Williams; J Winfield
Journal:  Ann Rheum Dis       Date:  2002-04       Impact factor: 19.103

6.  Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy.

Authors:  T Möttönen; L Paimela; M Leirisalo-Repo; H Kautiainen; J Ilonen; P Hannonen
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

7.  Work disability among two cohorts of women with recent-onset rheumatoid arthritis: a survival analysis.

Authors:  S Reisine; J Fifield; S Walsh; D Dauser
Journal:  Arthritis Rheum       Date:  2007-04-15

Review 8.  Pharmacological intervention in older patients with rheumatoid arthritis. Quality of life aspects.

Authors:  P Bendtsen; I Akerlind; J O Hörnquist
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

9.  Evidence for early disease-modifying drugs in rheumatoid arthritis.

Authors:  David L Scott
Journal:  Arthritis Res Ther       Date:  2003-12-16       Impact factor: 5.156

10.  Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores.

Authors:  Janine M Ouimet; Janet E Pope; Iris Gutmanis; John Koval
Journal:  Open Rheumatol J       Date:  2008-09-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.